



# RISK FACTORS, DAIGNOSIS AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: A REVIEW ARTICLE

Yadav Brajesh<sup>1</sup>,Jaiswal Nicky<sup>2</sup>,Aiman Shah<sup>3</sup>,Patil R.K.<sup>4</sup>

Department of Pharmacy Practice, Adesh institute of Pharmacy and biomedical science,  
Bathinda, Punjab (India)

## Abstract

IBD (inflammatory bowel disease), which involves CD (Crohn's disease) and UC (ulcerative colitis), is a constant incendiary problem of the gut with digestive just as foundational manifestations. Patients with IBD frequently experience times of wellbeing (for example reduction) substituting with times of infection action (for example backslide). This variability, combined with the possible long-haul entanglements of the infection and its related monetary and passionate loads, can be adversely affecting on various levels. One such level is wellbeing related personal satisfaction (HRQOL). The finding of a constant clinical problem builds feelings of anxiety and presents troublesome changes, which, thus, can modify HRQOL. For patients with IBD, such stressors might incorporate stomach inconvenience, rectal bleeding, and loose bowels, waste criticalness, hindered hunger, weight reduction, and need for long haul (immunosuppressant) medicine use, hospitalization, or medical procedure, among others. Thus, similarly as with patients with other constant illnesses, it isn't shocking that patients with IBD have more unfortunate HRQOL contrasted with sound controls.

Key words: Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Gastrointestinal tract, Health related quality of life

## INTRODUCTION

Definition: IBD (Inflammatory bowel disease) defined as illness (CD and UD) in which ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel sickness (IBD) of the colon that delivers the gastrointestinal (GIT) tract is inflamed for quite awhile which prompts delayed irritation harms the gastrointestinal tract. Looseness of the bowels, stomach pain, rectal bleeding, and weight reduction are some side effects of CD and UC. Aggravation is the most noticeable component. The two issues can strike teenagers and grown-ups, and both the orientation is similarly influenced. Although the clinical manifestation between the illnesses are identical, there are few differences between them <sup>[1]</sup>. Crohn's disease is one of the IBDs that affect people between the ages of 15 and 35. IBDs, unlike other inflammatory disorders, are difficult to treat. As a result, the system of defence is engaged, and a intestinal injury in some part. Ache, loose motion, shevering, and other clinical manifestation are few symptoms <sup>[2]</sup>. Crohn's disease can impact any part of the GIT tract, as well as colon, abdomen, esophagus, and even the mouth, in addition to the lower part of the small intestine. CD impacts the mouth, tonsil, and whole intestine. Colon mucosal layer is impacted by UC. The rectum and intestine are both impacted. The clinical manifestations are mild to severe, and the sometimes fetal .Because CD has an impact on the small intestine, which is crucial for absorbing nutrients, malnutrition is highly common in CD patients. Blood in the stool, intense pain, and diarrhea are all symptoms of ulcerative colitis, while in severe cases of Crohn's

disease, additionally; possibility of bleeding<sup>[3]</sup>. Rectal bleeding is less frequent in CD than it is in UC. More than half of persons with CD are deficient in folate and vitamin D, while more than half of people with UC are iron deficient.

## Types of IBD

**Ulcerative colitis** Ulcerative colitis (UC) is a backsliding and transmitting extreme idiopathic inflammatory bowel disease of the colon that produces nonstop mucosal irritation spreading from the rectum to the more proximal colon, with different degrees. On the planet, it is more successive than Crohn's infection.

**Crohn's disease:** Crohn's disease (CD) is a severe relapsing IBD characterized by a transmural granulomatous inflammation that can affect any region of the gastrointestinal system, most commonly the ileum, colon, or both<sup>[4]</sup>.

### Clinical manifestation:

The level of the irritation and the area of the illness influence the clinical show of IBD. Stomach pain, diarrhea, presence of blood stool, rectal discharge, and rectal urgency are a portion of the gastrointestinal signs. Patients with CD are bound to encounter stomach pain and persistent loose bowels, while those with UC are bound to encounter horrendous mucoid stool and rectal urgency, but ridiculous the runs can happen in CD with colonic contribution also. Foundational indications of IBD incorporate weariness, loss of craving, and non-irresistible fever, with weight reduction being especially well defined for Crohn's disease<sup>[5]</sup>.

Risk factors:

#### Environmental factors

In industrialised nations, IBD is more prevalent. "Hygiene hypothesis" is a theory offered as to why this has occurred. Simply put, because they have exceptionally clean houses, especially when they are young, people in these nations often have lower microbial exposure. Some persons may be more at risk for IBD as a result of these changes in gut flora<sup>[6]</sup>.

#### Genetic factors

The development of ulcerative colitis may be influenced by genetics. As a result, you are more likely to acquire an IBD if you have a close relative who has Crohn's disease or ulcerative colitis. According to Dr. Holmer, up to 20% of patients who have been diagnosed have first-degree relatives who have UC. Parents, siblings, and kids are considered first-degree relatives<sup>[7]</sup>.

#### Age and gender

Another potential risk factor is age. Although ulcerative colitis can occur at any age, it most frequently affects people under the age of 40. Researchers are still trying to understand why this is the case. The NIDDK states that individuals between the ages of 15 and 30 are most prone to develop UC<sup>[7]</sup>.


#### Genetic factors

#### Pathogenesis

Enterocytes, flagon cells, neuroendocrine cells, Paneth cells, M cells, and occupant gastrointestinal undifferentiated organisms make up the digestive epithelium. The external epithelium surface is covered by a bodily fluid layer made up essentially of defensin from Paneth cells and b-defensin from gastrointestinal epithelial cells<sup>[8]</sup>. As Peyer'spatches, an optional lymphoid organ, numerous natural and versatile resistant cells happen in the lamina propria. Design acknowledgment receptors on antigen-introducing cells (APC) like dendritic cells (DC) and macrophages recognize and initiate intraluminal microbes<sup>[9]</sup>. In APCs, autophagy clears these contaminations. Enacted APCs discharge proinflammatory cytokines, chemokines, and antimicrobial peptides prior to relocating to optional lymphoid organs to convey antigens to guileless CD4 Immune system microorganisms, which then mature into compelling T cells. Normally, naive CD4 Lymphocytes separate into Treg, however in CD and UC, they are directed to Th1 and Th17, separately.

Activated APCs and lymphocytes discharge chemokines, which make incendiary cells from the fundamental course move to the digestive tract<sup>[10]</sup>.

### Pathophysiology flowchart



### Diagnosis:

Lab Testing: Research facility testing Raised erythrocyte sedimentation rates and C-reactive protein (CRP), whiteness, and hypoalbuminemia could be used as intermediaries for disorder reality in biochemical tests. Distinguishing and checking faecal calprotectin neutrophil cytosolic protein conveyed into the stomach related framework lumen during dynamic gastrointestinal exacerbation is more unambiguous. Since it is homogeneously dispersed and stable at room temperature for up to 7 days<sup>23</sup>, squander calprotectin is a dependable pointer that contrasts well and other prominent (CD Endoscopic File of Seriousness [EIS] and easy (CRP) records. Not with standing the way that it is furthermore found in other red hot stomach diseases<sup>[10]</sup>.

Endoscopy: Different scoring procedures that coordinate clinical after effects, real revelations, and endoscopic or imaging evaluations have been used to gauge the earnestness of IBD disease as evident records to coordinate therapy and screen infection condition. The CDEIS and Direct Endoscopic Score for Conservative plate (SES-Collection) (which coordinate endoscopy disclosures for examination; the SES-CD is more clinical and practical and consequently preferred), as well as the CD Development Record (CDAI) or pediatric CDAI (which don't unite endoscopy revelations as a part of assessments) are the most normally elaborate scoring systems for CD. The Mayo score, which incorporates clinical incidental effects, endoscopic revelations, and specialists overall evaluations, is the most often elaborate scoring structure for UC<sup>[11]</sup>.

Sigmoidoscopy: Rigid sigmoidoscopy should be performed on all patients who present with diarrhoea unless there are immediate plans to undergo flexible sigmoidoscopy. The loss of vascular pattern, granularity, friability, and ulceration of the rectal mucosa are all macroscopic hallmarks of UC. Even if there are no macroscopic alterations, a rectal sample for histology is recommended<sup>[12]</sup>.

Imaging: To reduce unnecessary absorbing exposure to radiation, clinicians should discuss neuro imaging with an authorized radiologist. There ought to be where imaging results might be broke down in the viewpoint of the patient history so that suitable treatment can be arranged <sup>[13]</sup>.

## Management of IBD

### Non pharmacological treatment of Inflammatory Bowel Disease

General measures: IBD patients are more vulnerable to malnutrition, water and electrolyte imbalances, chronic anemia and high homocysteine levels, among other serious condition, can put their lives in jeopardy. As a result, proper symptomatic treatment is required. Water and electrolyte balance, as well as acid-base balance, should be restored. Patients who are anaemic should be transfused. Human albumin should be injected into hypoproteinemic patients. BMI, iron, calcium, and vitamins (particularly vitamin D and B12) should all be checked and modified as needed. Patients with serious illnesses should receive nutritional assistance treatment. If enteral nourishment is insufficient, parenteral nutrition might be used to complement it<sup>[14]</sup>. Anticholinergic or anti diarrheal medicines should be used as needed by patients with abdominal pain and diarrhea.

Diet: Nutritional influences the formation of absorbable metabolites<sup>[15]</sup> which are crucial mediators in the interaction between diet, the gut microbiome and the host<sup>[16]</sup>. Diet may therapy impact the IBD clinical manifestation, illness activity, diagnosis of IBD. The course of IBD will be impacted by the dietary elements that have proinflammatory characteristics. Dietary inflammatory index (DII) is measure that quantifies the potential inflammatory impact of nutrition and is connected to international standard. It is based on huge body of literature and data of population. A new study concluded that nutritional design with huge DII can enlarge the danger of Crohn's disease<sup>[17]</sup>. It represented that DII is firmly correspond with illness activity in Crohn's disease patients and there is no association between DII and illness activity of ulcerative colitis <sup>[18]</sup>. Investigating the impact of dietary treatments on IBD disease activity aids in the development of dietary recommendations for patients. More than half of IBD patients were found to be lacking in microelements like as iron, vitamin B12, vitamin D, vitamin K, and folic acid, according to a study <sup>[19]</sup>. Vitamin D supplementation, which can influence the immune response and reduce inflammation, has been shown to enhance the treatment outcomes of person with inflammatory bowel disease because the agile elements of vitamin D [1,25-(OH)D3] react with T cells and regulates the immunological response mediated by T cells (Vitamin D can further boost the anti-inflammatory effect by inhibiting dendritic cell inflammatory activity, inducing antimicrobial activity, and regulating cytokine synthesis <sup>[20]</sup>.

### Mood and psychology

Abdominal pain, diarrhea, mucinous blood, and other symptoms are common in people with inflammatory bowel disease (IBD). IBD patients are prone to worry, despair, and other negative feelings due to repeated symptoms and long-term medicine, which places a significant financial strain on the family <sup>[22]</sup>. Patients and their families should be encouraged to learn everything there is to know about their illness. They must be mentally prepared and understand how to deal with the symptoms effectively. Patients in the active phase of their sickness should get enough rest, appropriately expel their negative feelings, and avoid putting themselves under too much psychological stress<sup>[23]</sup>. To decrease the occurrence of the illness, they are encouraged to communicate with others and to comply with therapy<sup>[24]</sup>.

### General Treatment Considerations

- IBD treatment should be based on the following:

Symptoms/disease severity

Co morbidities

Goal of remission



## 5-aminosalicylates

Traditional sulfasalazine (SASP) and other forms of 5-aminosalicylic acid (5-ASA) medications are the most common aminosalicylates for IBD. SASP has been used to treat IBD for over 80 years and is made up of 5-ASA and sulphapyridine (SP) through diazobonding. Senescence-associated secretory phenotype is the prodrug, SP is the carrier, and 5-aminosalicylates is the active part in the therapy of inflammatory bowel disease [25]. 5-Aminosalicylates and Senescence-associated secretory phenotype MOA (modes of action) incorporate interference with arachidonic acid ingestion (transformation from PG and IL), forage of O2 types, and affect on activity of WBC and production of cytokine [26]. Oh-oka et al. proposed a distinctive anti-inflammatory mechanism for the management of colitis. Through the aryl hydrocarbon receptor pathway, 5-ASA could activate managerial White blood cells (Tregs) in the colon. 5-aminosalicylates (5-ASAs) are the first-line drug for provoking and staying aware of reduction in UC patients; 5-ASAs are secured and by and large around persevered. In any case, their sufficiency in patients with Album is at this point limited [27]. For delicate to unassumingly powerful proctitis, 1-g mesalamine suppository once ordinary is the appropriate starting treatment.

## Corticosteroids

Corticosteroids are profoundly fruitful for laying out reduction in people with dynamic IBD; by the by, they don't keep up with abatement, and their foundational impacts are disturbing to the two patients and specialists [28]. Prednisolone enlistment portions range from 0.5 to 1.0 mg/kg/day. 11 Patients with serious UC ought to be owned up to the medical clinic for intravenous corticosteroid therapy [29]. Corticosteroids ought to likewise be given to people whose side effects deteriorate, the individuals who have had ongoing rectal draining for over 14 days, and mesalamine-safe patients who have not gotten enduring abatement from all protests following 40 days of appropriate 5-ASA treatment with light movement. Budesonide or prednisolone is a reasonable first-line commencement drug for moderate - to - energetic or serious CD [30].

## Thiopurine

For even more than four decades, azathioprine (AZA) and 6-mercaptopurine (6-MP) are often used to manage CD and UC, and both are effective for induction and maintenance [31]. In a Systematic assessment of the efficiency of AZA and MP for generating cure in individuals with active CD, thiopurine treatment was found to be more effective than placebo treatment (OR:2.36, 95 percent CI: 1.57e3.53). AZA and 6-MP induction dosages are 1.5e2.5 mg/kg/d and 0.75e1.5 mg/kg/d, respectively. The late onset of action of thiopurine therapy, on the other hand, precludes it from being used as a solo initial treatment for active disease [32]. In individuals with corticosteroid-dependent or -resistant illnesses, thiopurines are suggested. The SONIC research found that infliximab with AZA is much more efficient than infliximab alone for maintaining steroid-free status [33].

## Methotrexate

Methotrexate is very well with a successful initiation and treatment therapy for CD64, [34] patients, and it could be a viable alternative, particularly for thiopurine-intolerant individuals. In a recent Cochrane study, 15 mg/week of intramuscular methotrexate was found to be considerably more efficacious than placebo in maintaining remission in CD patients. (Risk ratio: 1.67, 95% confidence interval: 1.05e2.67)

## Ciclosporin

(An unapproved treatment for UC that is administered orally or intravenously.) Ciclosporin (CsA) is a calcineurin inhibitor that prevents T-cell subgroups from clonally expanding. It works quickly and effectively in the treatment of serious UC. Iv CsA is a fast-acting survival treatment for people with chronic colitis who may face colon resection, but its usage is contentious due to toxicity and a high long-term rate of failure [35]. Smaller doses (2 mg/kg/day IV), orally micro emulsion, cyclosporine, or used as single agent without corticosteroids can all help to decrease toxicity. The medicine

should only be used for 3–6 months at a time, and its primary purpose is to act as a bridge to thiopurine treatment. CsA had no therapeutic value in CD, according to a Meta evaluation of multiple randomized clinical trials [36].

### Anti-TNF Therapy

Infliximab (IFX) is a phenomenal enemy of TNF antisera with remarkable calming properties, which might be interceded by combustible cell demise. Adequacy in both dynamic and fistulating Disc has been demonstrated in various controlled preliminaries. The Public Foundation of Clinical Greatness has created rules for the utilization of infliximab<sup>[37]</sup>. In a multicenter, double investigation of 108 patients with moderate to serious CD who had neglected to answer 5-ASA, corticosteroids, as well as immunomodulators, 5 mg/kg IFX delivered a 81 percent reaction rate at 4 weeks, contrasted with 17% with fake treatment. Reaction times differed, yet by week 12, 48 percent of the individuals who got 5 mg/kg actually had a reaction<sup>[38]</sup>.

### Conclusion

To summarise, preventing complications and ensuring positive results, early diagnosis and care of IBDs are essential. Risk assessment, disease activity, and the patient's clinical characteristics should all be taken into consideration when choosing the best first-line medication. At the moment, aminosalicylates, CSS, immunomodulators, and biologics are the main medications used to treat IBD. However, many patients either lose responsiveness over time or are unable to attain clinical remission after treatment.

### References

1. Baig, M. M., Fatima, S. A. R. A., Fatima, M. E. H. R. U. Q., Siddiqui, S. H. A. H. E. D. A., Ali, S. A., & Ilyas, M. N. (2016). Prescription pattern and cost of illness (COI) of inflammatory bowel disease (IBD) in a tertiary care hospital. *Int J Pharm PharmSci*, 9, 44-7
2. L., Zhong, L. H., Wen, Y., Liu, T. W., Li, X. Y., Hou, Z. K., ... & Liu, F. B. (2017). Inflammatory bowel disease-specific health-related quality of life instruments: a review of measurement properties. *Health and quality of life outcomes*, 15(1), 1-13.
3. K. M., Selinger, C. P., Gracie, D. J., & Ford, A. C. (2021). Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. *Neurogastroenterology & Motility*, e14256.
4. Knowles, S. R., Graff, L. A., Wilding, H., Hewitt, C., Keefer, L., & Mikocka-Walus, A. (2018). Quality of life in inflammatory bowel disease: a systematic review and meta-analyses—part I. *Inflammatory bowel diseases*, 24(4), 742-751
5. Peyrin-Biroulet, L., Cieza, A., Sandborn, W. J., Coenen, M., Chowers, Y., Hibi, T., ... & International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. (2012). Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. *Gut*, 61(2), 241-247.
6. S. R., Keefer, L., Wilding, H., Hewitt, C., Graff, L. A., & Mikocka-Walus, A. (2018). Quality of life in inflammatory bowel disease: a systematic review and meta-analyses—part II. *Inflammatory bowel diseases*, 24(5), 966-976.
7. Hanna, P. (2018). *A Study on Knowledge Assessment and Quality of Life in Inflammatory Bowel Disease Patient* (Doctoral dissertation, KMCH College of Pharmacy, Coimbatore).
8. T., Flauti, D., Abenavoli, L., Boccuto, L., Suraci, E., Marasco, R., ... & Lizza, F. (2020). The reality of patient-reported outcomes of health-related quality of life in an Italian cohort of patients with inflammatory bowel disease: Results from a cross-sectional study. *Journal of clinical medicine*, 9(8), 2416.
9. Scotinotis I, Rubesin SE, Ginsberg G. Imaging modalities in inflammatory Bowel disease. *Gastroenterol Clin N Am* 1999;28:391–421.
10. Bischoff SC, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, et al. ESPEN practical guideline: clinical nutrition in inflammatory bowel disease. *Clin Nutr.* (2020) 39:632–53. Doi: 10.1016/j.clnu.2019.11.002.

11. Papa A, Gerardi V, Marzo M, Felice C, Rapaccini GL, Gasbarrini A. Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. *World J Gastroenterol.* (2014) 20:3173–9. doi: 10.3748/wjg.v20.i12.3173
12. Lee D, Albenberg L, Compher C, Baldassano R, Piccoli D, Lewis JD, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gastroenterology.* (2015) 148:1087–106. Doi: 10.1053/j.gastro.2015.01.007
13. Tilg H, Moschen AR. Food, immunity, and the microbiome. *Gastroenterology.* (2015) 148:1107–19. Doi: 10.1053/j.gastro.2014.12.036
14. Shivappa N, Steck SE, Hurley TG, Hussey JR, Hébert JR. Designing and developing a literature-derived, population-Based dietary inflammatory index. *Public Health Nutr.* (2014) 17:1689–96. Doi: 10.1017/S1368980013002115
15. Hébert JR, Shivappa N, Wirth MD, Hussey JR, Hurley TG. Perspective: the dietary inflammatory index (DII)-lessons learned, Improvements made, and future directions. *Adv Nutr.* (2019) 10:185–95. Doi: 10.1093/advances/nmy071
16. Lewis JD, Abreu MT. Diet as a trigger or therapy for Inflammatory bowel diseases. *Gastroenterology.* (2017) 152:398–414.e6. doi: 10.1053/j.gastro.2016.10.019
17. Lamers CR, de Roos NM, Witterman BJM. The association between Inflammatory potential of diet and disease activity: results from a Cross-sectional study in patients with inflammatory bowel disease. *BMC Gastroenterol.* (2020) 20:316. Doi: 10.1186/s12876-020-01435-4
18. Mirmiran P, Moslehi N, Morshedzadeh N, Shivappa N, Hébert JR, Farsi F, et al. Does the inflammatory potential of diet affect disease Activity in patients with inflammatory bowel disease? *Nutr J.* (2019) 18:65. Doi: 10.1186/s12937-019-0492-9
19. Weissshof R, Chermesh I. Micronutrient deficiencies in inflammatory Bowel disease. *Curr Opin Clin Nutr Metab Care.* (2015) 18:576–81. doi: 10.1097/MCO.0000000000000226
20. Reich KM, Fedorak RN, Madsen K, Kroeker KI. Vitamin D improves Inflammatory bowel disease outcomes: basic science and clinical review. *World J Gastroenterol.* (2014) 20:4934–47. Doi: 10.3748/wjg.v20.i17.4934
21. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation As primary therapy to modify the course of Crohn's disease. *Aliment Pharmacol Ther.* (2005) 21:921–31. Doi: 10.1111/j.1365-2036.2005.02424.x
22. PUNCHARD NA, Greenfield SM, Thompson RP. Mechanism of Action of 5-aminosalicylic acid. *Mediators Inflamm.* (1992) 1:151–65. Doi: 10.1155/S0962935192000243
23. Oh-Oka K, Kojima Y, Uchida K, Yoda K, Ishimaru K, Nakajima S, et al. Induction of colonic regulatory t cells by mesalamine by activating the Aryl hydrocarbon receptor. *Cell Mol Gastroenterol Hepatol.* (2017) 4:13551. doi: 10.1016/j.jcmgh.2017.03.010
24. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO, Steinhart AH. Corticosteroids for maintenance of remission in Crohn's disease. 2003.
25. Truelove SC, Jewell DP. Intensive intravenous regimen for Severe attacks of ulcerative colitis. *Lancet* 1974;1(7866):1067e70.
26. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. *Am J Gastroenterol* 2005;100(11):2478e85.
27. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in Ulcerative colitis. *Cochrane Database Syst Rev* 2012;(9):CD000478.
28. Prefontaine E, Sutherland LR, MacDonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease (Review). *Cochrane Collab* 2010.
29. Gomollo'n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3<sup>rd</sup> European evidence-based consensus on The diagnosis and management of Crohn's disease 2016: Part1: diagnosis and medical management. *J Crohn's Colitis* 2017;11(1):3e25.

30. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. *Ann Intern Med* 1995;122:132e42.
31. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010;362(15):1383e95.
32. Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology* 2014;146(2):392e400. E3.
33. Hawthorne AB. Cyclosporin and refractory colitis. *Eur J Gastroenterol Hepatol* 2003;15:239–44.
34. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med* 1994;330:1841–5. 64 D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. *Gastroenterology* 2001;120:1323–9.
35. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. *Gastroenterology* 2003;125:1025–31.
36. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. *Inflamm Bowel Dis* 1998;4:276–9.
37. Actis GC, Bresso F, Astegiano M, et al. Safety and efficacy of azathioprine in the maintenance of cyclosporin-induced remission of ulcerative colitis. *Aliment Pharmacol Ther* 2001;15:131–7.
38. Feagan BG. Cyclosporin has no proven role as a therapy for Crohn's disease. *Inflamm Bowel Dis* 1995;1:335–9.

